
Can-Fite BioPharma Ltd. CANF
$ 2.14
0.45%
Country |
|
IPO year |
- |
Industry |
Biotechnology |
Stock Exchange |
NYSE AMERICAN |
Shares |
1.65 M |
Market Cap[1] |
$ 3.52 M |
EBITDA (LTM) |
$ -9.93 M |
P/E (LTM) |
-0.373534 |
P/S (LTM) |
9.064306 |
EPS (LTM) |
-5.97 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
|
BeyondSpring
BYSI
|
$ 0.79 | 2.12 % | $ 32.5 M | Nasdaq Capital Market | ||
|
Cabaletta Bio
CABA
|
$ 2.08 | 4.0 % | $ 209 M | Nasdaq Global Select Market | ||
|
Capricor Therapeutics
CAPR
|
$ 7.78 | 0.11 % | $ 362 M | Nasdaq Capital Market | ||
|
Catalyst Biosciences
CBIO
|
$ 13.94 | 0.42 % | $ 1.25 B | Nasdaq Capital Market | ||
|
C4 Therapeutics
CCCC
|
$ 2.99 | 1.36 % | $ 248 M | Nasdaq Global Select Market | ||
|
Codexis
CDXS
|
$ 1.39 | 2.21 % | $ 121 M | Nasdaq Global Select Market | ||
|
Cerus Corporation
CERS
|
$ 2.34 | 2.63 % | $ 446 M | Nasdaq Global Market | ||
|
Certara
CERT
|
$ 10.07 | 7.59 % | $ 1.62 B | Nasdaq Global Select Market | ||
|
Cullinan Management
CGEM
|
$ 16.04 | 3.42 % | $ 966 M | Nasdaq Global Select Market | ||
|
Compugen Ltd.
CGEN
|
$ 2.31 | 0.43 % | $ 216 M | Nasdaq Global Market,SPB | ||
|
Coherus BioSciences
CHRS
|
$ 1.12 | 0.86 % | $ 131 M | Nasdaq Global Market | ||
|
Celldex Therapeutics
CLDX
|
$ 32.59 | 2.97 % | $ 2.16 B | Nasdaq Global Select Market | ||
|
CollPlant Biotechnologies Ltd.
CLGN
|
$ 3.41 | 1.46 % | $ 41.6 M | Nasdaq Capital Market | ||
|
Cellectis S.A.
CLLS
|
$ 1.41 | 0.48 % | $ 141 M | Nasdaq Global Market | ||
|
Cellectar Biosciences
CLRB
|
$ 1.67 | 0.56 % | $ 4.36 M | Nasdaq Capital Market | ||
|
CNS Pharmaceuticals
CNSP
|
$ 5.3 | 0.7 % | $ 2.35 M | Nasdaq Capital Market | ||
|
Cocrystal Pharma
COCP
|
$ 1.11 | 1.72 % | $ 12.5 M | Nasdaq Capital Market | ||
|
Collegium Pharmaceutical
COLL
|
$ 21.87 | 0.05 % | $ 692 M | Nasdaq Global Select Market | ||
|
Corcept Therapeutics Incorporated
CORT
|
$ 122.03 | 4.99 % | $ 12.7 B | Nasdaq Capital Market,SPB | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
$ 5.85 | 0.16 % | $ 77.9 M | Nasdaq Global Market | ||
|
Cardiff Oncology
CRDF
|
$ 1.14 | 1.79 % | $ 76.2 M | Nasdaq Capital Market | ||
|
Curis
CRIS
|
$ 0.79 | 0.1 % | $ 10.4 M | Nasdaq Global Market | ||
|
CorMedix
CRMD
|
$ 7.26 | 0.97 % | $ 523 K | Nasdaq Global Market | ||
|
CRISPR Therapeutics AG
CRSP
|
$ 57.34 | 3.45 % | $ 5.16 B | Nasdaq Global Market,SPB | ||
|
Corvus Pharmaceuticals
CRVS
|
$ 10.74 | 0.09 % | $ 848 M | Nasdaq Global Market | ||
|
Champions Oncology
CSBR
|
$ 4.97 | 0.61 % | $ 68.7 M | Nasdaq Capital Market | ||
|
CytomX Therapeutics
CTMX
|
$ 2.58 | 0.78 % | $ 356 M | Nasdaq Global Select Market | ||
|
Citius Pharmaceuticals
CTXR
|
$ 0.52 | 0.4 % | $ 5.75 M | Nasdaq Capital Market | ||
|
Cue Biopharma
CUE
|
$ 24.36 | 1.27 % | $ 2.31 B | Nasdaq Capital Market,SPB | ||
|
CEL-SCI Corporation
CVM
|
$ 2.42 | 4.76 % | $ 19.4 M | NYSE American,SPB | ||
|
Cytokinetics, Incorporated
CYTK
|
$ 62.7 | 0.2 % | $ 7.53 M | Nasdaq Global Select Market,SPB | ||
|
Daré Bioscience
DARE
|
$ 0.84 | 0.04 % | $ 9.39 M | Nasdaq Capital Market | ||
|
DBV Technologies S.A.
DBVT
|
$ 10.44 | 0.47 % | $ 1.46 B | Nasdaq Global Select Market | ||
|
DiaMedica Therapeutics
DMAC
|
$ 8.42 | 2.31 % | $ 396 M | Nasdaq Capital Market | ||
|
Denali Therapeutics
DNLI
|
$ 19.91 | 0.41 % | $ 3.44 B | Nasdaq Global Select Market,SPB | ||
|
Precision BioSciences
DTIL
|
$ 6.31 | 0.16 % | $ 80.9 M | Nasdaq Global Select Market | ||
|
Dyadic International
DYAI
|
$ 0.45 | 0.31 % | $ 16.3 M | Nasdaq Capital Market | ||
|
Editas Medicine
EDIT
|
$ 2.79 | 6.49 % | $ 248 M | Nasdaq Global Select Market,SPB | ||
|
Edesa Biotech
EDSA
|
$ 3.91 | 1.3 % | $ 22.2 M | Nasdaq Capital Market | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
$ 0.36 | 0.36 % | $ 16.5 M | Nasdaq Capital Market | ||
|
Enanta Pharmaceuticals
ENTA
|
$ 12.6 | 0.93 % | $ 269 K | Nasdaq Global Select Market,SPB | ||
|
Entera Bio Ltd.
ENTX
|
$ 2.62 | 0.69 % | $ 121 M | Nasdaq Capital Market | ||
|
Equillium
EQ
|
$ 1.45 | 2.84 % | $ 83.1 M | Nasdaq Global Market | ||
|
Eton Pharmaceuticals
ETON
|
$ 55.62 | 0.47 % | $ 1.5 B | Nasdaq Global Market | ||
|
Evogene Ltd.
EVGN
|
$ 0.4 | 3.54 % | $ 3.15 M | Nasdaq Global Market | ||
|
Exelixis
EXEL
|
$ 58.85 | 0.79 % | $ 16 B | Nasdaq Global Select Market,SPB | ||
|
EyePoint Pharmaceuticals
EYPT
|
$ 3.15 | 0.62 % | $ 231 K | Nasdaq Global Market | ||
|
Fate Therapeutics
FATE
|
$ 2.43 | 4.74 % | $ 289 M | Nasdaq Global Market,SPB | ||
|
Fortress Biotech
FBIO
|
$ 2.09 | 2.96 % | $ 58.3 M | Nasdaq Capital Market |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.